Diagnostics in China
This article was originally published in The Gray Sheet
Executive Summary
China Medical Technologies broadens its in vitro diagnostic market presence in China through the purchase of Beijing Bio-Ekon Biotechnology for $28.8 million, announced Nov. 26. The acquired firm offers enzyme-linked immunosorbent assays and semi-automatic, enhanced chemiluminescence immunoassay (ECLIA) analyzers and related reagents in China, and expects to seek approval in China next year for a fully automatic version. CMT, which also offers ECLIA products, acquired fluorescent in situ hybridization diagnostics technology in February (1"The Gray Sheet" Feb. 12, 2007, p. 8)